Cart
sales@molnova.com
BP-1-102
CAS No. 1334493-07-0
BP-1-102( BP-1-102 | BP1-102 | BP 1-102 | BP1102 )
Catalog No. M11334 CAS No. 1334493-07-0
An orally bioavailable, small-molecule inhibitor of STAT3 with Kd of 504 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 42 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 200 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 494 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBP-1-102
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn orally bioavailable, small-molecule inhibitor of STAT3 with Kd of 504 nM.
-
DescriptionAn orally bioavailable, small-molecule inhibitor of STAT3 with Kd of 504 nM; blocks Stat3-pTyr peptide interactions and Stat3 activation at 4-6.8 uM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells; suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and KLF8, blocks Stat3-NF-κB cross-talk, and enhances E-cadherin expression; inhibits growth of human breast and lung tumor xenografts.
-
In VitroBP-1-102 binds Stat3 with an affinity KD of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro, with an IC50 value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8.
-
In VivoMice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth.
-
SynonymsBP-1-102 | BP1-102 | BP 1-102 | BP1102
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1334493-07-0
-
Formula Weight626.5915
-
Molecular FormulaC29H27F5N2O6S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 33 mg/mL
-
SMILESO=C(O)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(=O)(C4=C(F)C(F)=C(F)C(F)=C4F)=O)=O)C=C1O
-
Chemical NameBenzoic acid, 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-2-hydroxy-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhang X, et al. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8.
2. De Simone V, et al. Oncogene. 2015 Jul;34(27):3493-503.
3. Resetca D, et al. J Biol Chem. 2014 Nov 21;289(47):32538-47.
molnova catalog
related products
-
ML116
A novel selective STAT3 inhibitor with IC50 of 4.2 uM.
-
Hydrazinocurcumin
Hydrazinocurcumin is a synthetic curcumin derivative that inhibits the proliferation of bovine aortic endothelial cells (BAECs) with IC50 of 520 nM without cytotoxicity.
-
NT219
NT219 is a dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3, enhances the aggregation of misfolded prion protein NT219 affects the levels of certain molecular chaperones and inhibits STAT3 phosphorylation NT219 is useful for the study of cancer and neurodegenerative diseases.
